There are many different types of drugs used for hormone therapy in the treatment of prostate cancer. One of the newer classes of drugs include the GnRH antagonists. Degarelix (aka Firmagon) is the one drug in this class that is currently approved for prostate cancer. Degarelix, like the other hormone therapy drugs, was developed to [...]
The newest gonadotropin-releasing hormone (GnRH) antagonist therapy drug, degarelix (aka Firmagon) has become more commonly used in everyday clinical practice as an alternative hormone therapy treatment drug (ADT). Given that its use has become common it is important to understand both its safety and efficacy as compared to our older standard drugs. The best way [...]
Many men with advanced prostate cancer who are on hormone therapy (ADT) use one of the newer drugs, degarelix (Firmagon) to achieve a state of castration. Degarelix is considered a superior drug for initiating ADT because it is not accompanied with a PSA flare that is common with the older luteinizing hormone-releasing hormone (LHRH) agonists [...]
Prostate cancer is commonly associated with lower urinary tract symptoms (LUTS). The use of GnRH agonists or antagonists (first line ADT) is widely used as the primary treatment for advanced prostate cancer (pc) and/or to reduce prostate volume (TPV). It is thought that the ADT contributes to the development of LUTS. Researchers pooled multiple other [...]
New data, published September 1 in the Journal of Urology, shows that Firmagon® (degarelix) which is a gonadotropin-releasing hormone therapy (GnRH) given to men with advanced prostate cancer may be superior to leuprolide when used over three years. This new study (CS21A) was an open-label extension of the Phase III study (CS21) in which Firmagon® [...]